Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils.
Leukocytes use urokinase receptors (uPAR; CD87) in adhesion, migration, and proteolysis of matrix proteins. Typically, uPAR clusters at cell-substratum interfaces, at focal adhesions, and at the leading edges of migrating cells. This study was undertaken to determine whether uPAR clustering mediates activation signaling in human polymorphonuclear neutrophils. Cells were labeled with fluo-3/AM to quantitate intracellular Ca2+ ([Ca2+]i) by spectrofluorometry, and uPAR was aggregated by Ab cross-linking. Aggregating uPAR induced a highly reproducible increase in [Ca2+]i (baseline to peak) of 295 +/- 37 nM (p = 0.0002). Acutely treating cells with high m.w. urokinase (HMW-uPA; 4000 IU/ml) produced a response of similar magnitude but far shorter duration. Selectively aggregating uPA-occupied uPAR produced smaller increases in [Ca2+]i, but saturating uPAR with HMW-uPA increased the response to approximate that of uPAR cross-linking. Cross-linking uPAR induced rapid and significant increases in membrane expression of CD11b and increased degranulation (release of beta-glucuronidase and lactoferrin) to a significantly greater degree than cross-linking control Abs. The magnitude of degranulation correlated closely with the difference between baseline and peak [Ca2+]i, but was not dependent on the state of uPA occupancy. By contrast, selectively cross-linking uPA-occupied uPAR was capable of directly inducing superoxide release as well as enhancing FMLP-stimulated superoxide release. These results could not be duplicated by preferentially cross-linking unoccupied uPAR. We conclude that uPAR aggregation initiates activation signaling in polymorphonuclear neutrophils through at least two distinct uPA-dependent and uPA-independent pathways, increasing their proinflammatory potency (degranulation and oxidant release) and altering expression of CD11b/CD18 to favor a firmly adherent phenotype.
Sitrin
R G
RG
Pulmonary and Critical Care Medicine Division, University of Michigan, Ann Arbor, MI 48109, USA. rsitrin@umich.edu
Pan
P M
PM
Harper
H A
HA
Todd
R F
RF
Harsh
D M
DM
Blackwood
R A
RA
D002118:Calcium / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000096:biosynthesis; D015550:Cell Degranulation / Q000276:immunology; D003594:Cytoplasmic Granules / Q000276:immunology / Q000378:metabolism; D004792:Enzyme Precursors / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D007424:Intracellular Fluid / Q000378:metabolism; D016177:Macrophage-1 Antigen / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D010960:Plasminogen Activators / Q000378:metabolism; D011940:Receptor Aggregation / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000378:metabolism* / Q000502:physiology; D055293:Receptors, Urokinase Plasminogen Activator; D015398:Signal Transduction / Q000276:immunology*; D013481:Superoxides / Q000378:metabolism
D015815:Cell Adhesion Molecules; D004792:Enzyme Precursors; D016177:Macrophage-1 Antigen; C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D013481:Superoxides; D010960:Plasminogen Activators; D002118:Calcium